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Abstract
 
The important role played by CD8
 
 
 
 T lymphocytes in the control of parasitic and viral infec-
tions, as well as tumor development, has raised the need for the development of adjuvants ca-
pable of enhancing cell-mediated immunity. It is well established that protective immunity
against liver stages of malaria parasites is primarily mediated by CD8
 
 
 
 T cells in mice. Activa-
tion of natural killer T (NKT) cells by the glycolipid ligand, 
 
 
 
-galactosylceramide (
 
 
 
-GalCer),
causes bystander activation of NK, B, CD4
 
 
 
, and CD8
 
 
 
 T cells. Our study shows that coad-
ministration of 
 
 
 
-GalCer with suboptimal doses of irradiated sporozoites or recombinant vi-
ruses expressing a malaria antigen greatly enhances the level of protective anti-malaria immu-
nity in mice. We also show that coadministration of 
 
 
 
-GalCer with various different
immunogens strongly enhances antigen-specific CD8
 
 
 
 T cell responses, and to a lesser degree,
Th1-type responses. The adjuvant effects of 
 
 
 
-GalCer require CD1d molecules, V
 
 
 
14 NKT
cells, and interferon 
 
 
 
. As 
 
 
 
-GalCer stimulates both human and murine NKT cells, these find-
ings should contribute to the design of more effective vaccines against malaria and other intra-
cellular pathogens, as well as tumors.
Key words:
 
 
 
-galactosylceramide • NKT cells • adjuvant • malaria vaccines • CD8
 
 
 
 T cells
 
Introduction
 
During the last few years, evidence has accumulated indi-
cating that the cellular immune response plays a critical role
in defense against viral, bacterial, and parasitic infections, as
well as tumor development (1–3). At present, conventional
vaccine delivery systems and the adjuvants approved for
human use (aluminum salts and MF59) are poor at induc-
ing CD8
 
 
 
 T cell responses (4). The development of adju-
vants capable of eliciting a robust, specific CD8
 
 
 
 T cell re-
sponse is an active area of research (5).
The feasibility of the development of a vaccine against
malaria is supported by the fact that immunization with ra-
diation-attenuated sporozoites can elicit sterile immunity
against challenge with 
 
Plasmodium spp
 
. sporozoites in mice,
monkeys, and humans (6, 7). A large number of studies
performed in animal models and a few epidemiological
studies in human subjects indicate a central role of CD8
 
 
 
 T
lymphocytes in protection against the liver stages of malaria
(8–12). These studies have led us to search for a malaria
vaccine based on its ability to induce a protective CD8
 
 
 
 T
cell response. Recently, recombinant attenuated viruses,
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such as adenovirus (13) and Sindbis virus (14) given as sin-
gle immunizing doses, and influenza and vaccinia viruses
used together in a prime-boost strategy (15), have been
shown to potently induce malaria-specific CD8
 
 
 
 T cell re-
sponses in animal models.
NKT cells comprise a lymphocyte population character-
ized by expression of surface markers of natural killer cells
together with a semi-invariant T cell receptor (16). NKT
cells have the ability to produce a large amount of IFN-
 
 
 
and IL-4 promptly after their activation by in vivo adminis-
tration of anti-CD3 mAb or by 
 
 
 
-galactosylceramide (
 
 
 
-
GalCer),
 
*
 
 a glycolipid originally purified from a marine
sponge (17, 18). The administration of 
 
 
 
-GalCer, a ligand
of NKT cells, to mice immunized with an antigen has been
shown to influence the process of Th1/Th2 development.
One study has provided evidence that coadministration of
 
 
 
-GalCer with an antigen shifts the antigen-specific T cell
response toward Th1 cytokine production (19), whereas
other studies support Th2 polarization by 
 
 
 
-GalCer (20,
21). Furthermore, it has been suggested that the activation
of NKT cells by 
 
 
 
-GalCer may contribute to the genera-
tion of tumor-specific cytotoxic T cells (22), as well as in-
duction of Th1 cells responsive to cryptococcal antigens
(23). Finally, the administration of 
 
 
 
-GalCer to mice rap-
idly activates NK cells (24, 25), and increases the expression
of activation markers on T cells (26). Taken together, these
results have led to a hypothesis that the NKT cell ligand
 
 
 
-GalCer could be used as an adjuvant to modulate and/or
augment protective immune responses elicited by vaccines.
 
Materials and Methods
 
Parasites and Their Use for Immunization. Plasmodium yoelii
 
 (17X
NL strain) sporozoites were obtained by dissecting the mosquito
salivary glands as described (27). For immunization, sporozoites
were radiation-attenuated by exposing them to 12,000 rad, and
then injected intravenously into the tail vein or subcutaneously
into the base of the tail of the mice. 10
 
4
 
 or 10
 
5
 
 irradiated sporozoi-
tes (
 
 
 
-spz) were used to immunize mice for protection assay or an
enzyme-linked immunospot (ELISPOT) assay, respectively.
 
Immunization with Recombinant Viruses.
 
A suboptimal dose
(10
 
7
 
 PFU) of recombinant adenovirus expressing the entire 
 
P.
yoelii
 
 circumsporozoite (CS) protein, AdPyCS (13), was used to
immunize mice. The recombinant Sindbis virus expressing the
CD8
 
 
 
 T cell epitope (SYVPSAEQI) of 
 
P. yoelii
 
 CS protein,
SIN(Mal), and the recombinant Sinbis virus expressing the CD8
 
 
 
T cell epitope (RGPGRAFVTI) of HIV p18 protein, SIN(p18),
were constructed as described (14, 28), and 10
 
5
 
 PFU of the vi-
ruses were inoculated subcutaneously, as a suboptimal dose.
 
Mice.
 
BALB/c and B10.D2 mice were purchased from The
Jackson Laboratory and maintained under standard conditions in
our Departmental Animal Facility. V
 
 
 
14 NKT-deficient mice
(J
 
 
 
281
 
 
 
/
 
 
 
) were established by specific deletion of the J
 
 
 
281
gene segment with homologous recombination and aggregation
chimera techniques (27) and used after 3–4 backcrosses to BALB/c.
CD1d-deficient mice (CD1d
 
 
 
/
 
 
 
) were generated from embry-
 
onic stem cells of 129 origin and used after 7–8 backcrosses to
BALB/c (27). IFN-
 
 
 
 receptor-deficient mice (IFN-
 
  
 
R
 
 
 
/
 
 
 
)
were originally provided by Dr. Michel Aguet at Swiss Institute
for Experimental Cancer Research (Epalinges, Switzerland), and
used after three backcrosses to B10.D2 (29). Mice of either sex
were used at 6–8 wk.
 
 
 
-GalCer.
 
 
 
-GalCer, [(2S,3S,4R)-1-O-(
 
 
 
-D-galactopyrano-
syl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol], was synthe-
sized by Kirin Brewery (17). The original solution was dissolved
with 0.5% polysorbate-20 (Nikko Chemical) in 0.9% NaCl solu-
tion and diluted with PBS just before use.
 
Quantification of P. yoelii rRNA in the Liver of Sporozoite-inocu-
lated Mice by Real-time PCR.
 
Total liver RNA was isolated by
the method of Chomczynski and Sacchi from mice killed 42 h after
intravenous injection with 10
 
4
 
 
 
P. yoelii
 
 sporozoites. After reverse
transcription of the extracted RNA, cDNA was generated and its
amount analyzed by real-time PCR, using the ABI Prism 5700
Sequence Detection system (PE Biosystems; reference 30). Prim-
ers and fluorogenic probe with the following sequences were
custom designed using the ABI Prism primer Express software
(PE Biosystems), based on 
 
P. yoelii
 
 (17XNL) 18S rRNA sequence
(30). The primers, 5
 
 
 
-GGGGATTGGTTTTGACGTTTTTG-
CG-3
 
 
 
 (forward primer), and 5
 
 
 
-AAGCATTAAATAAAGCGA-
ATACATCCTTAT-3
 
 
 
 (reverse primer), were obtained from Op-
eron Technologies Inc. The specific fluorogenic probe, PyNYU,
5
 
 
 
-FAM-CAATTGGTTTACCTTTTGCTCTTT-TAMRA-3
 
 
 
,
was obtained from PE Biosystems, and was generated with 5-pro-
pyne-2
 
 
 
-deoxyuridine (turbo Taqman probe) to achieve a proper
Tm. The reaction mix contained 5 
 
 
 
l of 10
 
 
 
 Taqman buffer A
(PE Biosystems), 3.5 mM MgCl
 
2
 
, 200 
 
 
 
M dNTP, 0.3 
 
 
 
M for-
ward primer, 0.3 
 
 
 
M reverse primer, 50 nM turbo Taqman probe
PyNYU, 1.25 U AmpliTaq Gold DNA polymerase, and water up
to 50 
 
 
 
l final reaction volume. The temperature profile included
95
 
 
 
C for 10 min and 35 cycles of denaturation at 95
 
 
 
C for 15 s
and annealing/extension at 60
 
 
 
C for 1 min. The precise amount
of parasite-derived 18S cDNA molecules detected in this assay
was determined by linear regression analysis using C
 
T
 
 values ob-
tained from both liver samples and those obtained from a standard
curve generated with known amounts of plasmid 18S cDNA.
 
Quantification of Epitope-specific CD4
 
 
 
 and CD8
 
 
 
 T Cells by
ELISPOT Assay.
 
After coating 96-well nitrocellulose plates
(Millipore) with anti–mouse IFN-
 
 
 
 mAb, or anti–mouse IL-4
mAb overnight at room temperature, the wells were washed re-
peatedly and blocked with culture medium for 1 h at 37
 
 
 
C. The
MHC-compatible target cells, A20.2J B cell lymphoma, express-
ing both MHC class I and II H-2
 
d
 
 molecules, were incubated for
1 h at 37
 
 
 
C with the synthetic peptide representing the CD4
 
 
 
 T
cell epitope (YNRNIVNRLLGDALNGKPEEK) or CD8
 
 
 
 T
cell epitope (SYVPSAEQI) of the 
 
P. yoelii
 
 CS protein, or CD8
 
 
 
T cell epitope (RGPGRAFVTI) of the HIV p18 protein. After
irradiating the peptide-pulsed target cells, the cells were washed
and then added to the ELISPOT wells. Untreated target cells
were used as negative controls. Serially diluted lymphocytes iso-
lated from the spleen or lymph nodes of immunized mice were
cocultured with 1.5 
 
 
 
 10
 
5
 
 target cells in the ELISPOT wells. Af-
ter incubating the plates 24 h for IFN-
 
 
 
 detection or 48 h for IL-4
detection at 37
 
 
 
C and 5% CO
 
2
 
, the plates were treated as previ-
ously described (13), and the number of spots corresponding to
IFN-
 
 
 
 and IL-4 secreting cells determined.
 
Quantification of 
 
 
 
-GalCer–specific Cells by ELISPOT Assay.
 
The relative numbers of IFN-
 
 
 
 and/or IL-4 producing 
 
 
 
-Gal-
Cer–specific lymphocytes were determined using an ELISPOT
assay. Lymphocytes were isolated from the liver of wild-type and
 
*
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-galactosylceramide; CS, cir-
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IFN-
 
 
 
 R–deficient mice, as described (13). After 12 h incubation
with 100 ng/ml of 
 
 
 
-GalCer or vehicle at a cell density of 10
 
7
 
cells/ml, serially diluted lymphocytes, starting at 10
 
6
 
 cells per well,
were placed into ELISPOT wells coated with corresponding anti-
cytokine antibodies. After incubating the plates for 24 h at 37
 
 
 
C
and 5% CO
 
2
 
, the plates were developed as described (13).
 
Flow Cytometric Analysis Using CD1d/
 
 
 
-GalCer Tetramers.
 
 
 
-Gal-
Cer–specific lymphocytes were identified using CD1d/
 
 
 
-GalCer
tetrameric complexes, consisting of CD1d molecules and 
 
 
 
-Gal-
Cer, as described previously (31). Freshly isolated hepatic lym-
phocytes were incubated first with phycoerythrin (PE)-labeled
tetrameric complexes, followed by a second incubation with
FITC-labeled anti-CD3 monoclonal antibody. The cells were
then analyzed by a FACSCalibur™ instrument (Becton Dickin-
son) using CELLQuest™ software (Becton Dickinson).
 
Statistical Analysis.
 
Student’s 
 
t
 
 test was used for all compari-
sons. Only 
 
P
 
 values below 0.01 were considered significant. Data
are presented as mean values 
 
 
 
 SD.
 
Results
 
 
 
-GalCer Enhances Protective Anti-malaria Immunity.
 
To
learn whether protective anti-malaria immune response in-
duced by immunization with a suboptimal dose of irradi-
ated sporozoites could be enhanced by 
 
 
 
-GalCer, we im-
munized BALB/c mice intravenously with a suboptimal
dose (10
 
4
 
) of 
 
 
 
-spz together with different doses of 
 
 
 
-Gal-
Cer (0.5, 1, 2 
 
 
 
g). 2 wk later, we challenged different
groups of mice with 10
 
4
 
 live 
 
P. yoelii
 
 sporozoites, and mea-
sured the levels of protective anti-malaria immunity by de-
termining the amount of parasite-specific rRNA in the
liver with a highly sensitive real-time PCR (30). We found
that administration of 
 
 
 
-GalCer significantly enhanced, in
a dose-dependent manner, the level of protective immu-
nity (percent inhibition of liver stage development) elicited
by immunization with 
 
 
 
-spz (Fig. 1 A). The parasite load
in the livers of 
 
 
 
-spz–immunized mice administered with 2
 
 
 
g of 
 
 
 
-GalCer was 10 times smaller than that in the livers
of mice immunized with 
 
 
 
-spz alone.
We also determined the titers of anti-sporozoite antibod-
ies using an immunofluorescence assay (IFA) of air-dried 
 
P.
yoelii
 
 sporozoites, as well as the titers of antibody against the
CS protein, the major surface antigen of sporozoites, using
ELISA. The antibody titers were identical among the
groups of 
 
 
 
-spz–immunized mice regardless of whether or
not they received 
 
 
 
-GalCer (Fig. 1 A). Furthermore, we
determined the immunoglobulin isotype of the anti-CS an-
tibodies. No significant differences in IgE, IgG
 
1
 
, IG
 
2a
 
 or
IgM isotype profiles of anti-CS antibodies were detected
between 
 
 
 
-GalCer–treated and untreated mice (data not
shown). These results indicate that the anti-malarial hu-
moral response is not affected by 
 
 
 
-GalCer treatment.
We then examined the kinetics of this adjuvant activity
displayed by 
 
 
 
-GalCer by administering 2 
 
 
 
g of the gly-
colipid to BALB/c mice on the same day, 2 d before or 2 d
after intravenous immunization with 10
 
4
 
 
 
 
 
-spz. The high-
est level of protective anti-malaria immunity was elicited
when we administered 
 
 
 
-GalCer on the same day as 
 
 
 
-spz
(Fig. 1 B). Administration of 
 
 
 
-GalCer 2 d after 
 
 
 
-spz im-
munization did not significantly enhance the level of pro-
tective immunity induced by vaccination. Interestingly,
when we administered 
 
 
 
-GalCer 2 d before 
 
 
 
-spz immu-
nization, protective immunity was completely abolished. It
is possible that 
 
 
 
-GalCer, administered 2 d earlier, might
Figure 1.  -GalCer enhances pro-
tective anti-malaria immunity induced
by irradiated sporozoites and recombi-
nant viruses expressing a plasmodial
antigen. (A) Groups of BALB/c mice
were coinjected intraperitoneally with
different doses of  -GalCer (0.5, 1, or
2   g) or vehicle ( ), together with
intravenous immunization with P. yoelii
irradiated sporozoites ( -spz). 2 wk
later all groups of mice were challenged
with infective sporozoites, and the
amount of parasite ribosomal RNA in
the livers was measured by real-time
PCR. Sera from immunized and nonimmunized mice were
collected and their titers of anti-sporozoite antibodies assayed
by IFA. (B) A single dose of  -GalCer was administered 2 d
before ( 2), the same day (0) or 2 d after ( 2) immuniza-
tion with  -spz into BALB/c (black bars) or B10.D2 (white
bars) mice. (C) A group of BALB/c mice was immunized
subcutaneously with a recombinant adenovirus expressing
the P. yoelii CS protein, AdPyCS, together with subcutane-
ous administration of  -GalCer ( ) or vehicle ( ). (D) A
group of BALB/c mice was immunized subcutaneously with
a recombinant Sindbis virus expressing a CD8  T cell
epitope of the P. yoelii CS protein, SIN(Mal), together with
subcutaneous administration of  -GalCer ( ) or vehicle
( ). Asterisk (*) indicates a significant (P   0.01) difference between the two values using an unpaired t test. In B–D, all groups of mice were infected
with live P. yoelii sporozoites 2 wk later, and the parasite burden in the liver was determined, as described in panel A. Results are expressed as the mean
values   SD of five mice. 
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have eliminated the sporozoites before they could be pro-
cessed and presented by antigen-presenting cells, thereby
preventing the induction of a malaria-specific immune re-
sponse. We have previously shown that 
 
 -GalCer adminis-
tered 2 d before challenge with live sporozoites completely
eliminates the parasites from the liver in a manner depen-
dent on NKT cells and IFN-  (27). Similar kinetics of the
adjuvant activity of  -GalCer were observed in B10.D2
mice (Fig. 1 B).
To determine whether or not  -GalCer’s enhancement
of the protective immune response against malaria was a par-
ticular phenomenon related to  -spz immunization, or a
more general phenomenon independent of the immunogen
administered, we administered  -GalCer to BALB/c mice
on the same day as subcutaneous immunization with a sub-
optimal dose of recombinant adenovirus expressing the
whole P. yoelii CS protein, AdPyCS (13), or recombinant
sindbis virus expressing the CD8  T cell epitope of the CS
protein, SIN(Mal) (14). As shown in Fig. 1, C and D,  -Gal-
Cer significantly enhances the protective immune response
induced by immunization with a suboptimal dose of the two
different recombinant viruses. In the case of AdPyCS, the
protection was augmented almost 10 times to that of con-
trol, and in the case of SIN(Mal), the protection after coad-
ministration with  -GalCer was enhanced 3 times.
To further assess the adjuvant activity of  -GalCer coad-
ministered with vaccines, we monitored parasitemia, i.e.,
the presence of parasites in the blood, daily by microscopic
examination of thin blood smears. Briefly, we immunized
BALB/c mice either intravenously with 104  -spz or sub-
cutaneously with 107 PFU of AdPyCS, doses which other-
wise fail to confer protection against malaria, with or with-
out  -GalCer treatment. 2 wk later, we challenged all mice
with 50 viable P. yoelii sporozoites, and determined the oc-
currence of blood infection by monitoring parasitemia. We
found that 28 out of 30  -GalCer–treated,  -spz–immu-
nized mice were protected, while most of the  -GalCer–
untreated,  -spz–immunized mice developed malaria in-
fection (Table I). Similarly, administration of  -GalCer
together with AdPyCS strongly enhanced the protective
effect induced by a suboptimal dose of the virus. On the
other hand, administration of  -GalCer alone failed to pro-
tect the challenged mice. Overall, these results corroborate
the liver stage data (Fig. 1), and together indicate that  -Gal-
Cer administration increases the efficacy of a suboptimal
immunizing dose of both  -spz and recombinant viruses,
revealing a profound adjuvant effect.
 -GalCer Enhances T Cell Responses Elicited by Various
Vaccines. To determine which components of the malaria-
specific T cell response, i.e., CD4  and/or CD8  T cells,
are enhanced by coinjection of  -GalCer with  -spz, we
compared these immune parameters in  -spz–immunized
mice treated with or without the glycolipid. For this pur-
pose, we immunized BALB/c mice with 105   -spz, to-
gether with vehicle or  -GalCer. 2 or 6 wk later, we iso-
lated splenic lymphocytes and determined the numbers of
CS-specific, IFN- – and IL-4–secreting CD8  and CD4 
T cells by an ELISPOT assay (13). As shown in Fig. 2 A,
 -GalCer treatment strikingly enhanced the level of CS-
specific T cell responses elicited by  -spz at 2 wk after im-
munization. Specifically,  -GalCer increased the number of
IFN- –secreting CS-specific CD8  T cells approximately
sevenfold compared with that induced by  -spz immuniza-
tion alone. The number of IFN-  secreting CS-specific
CD4  T cells was also significantly increased, albeit to a
lesser degree. More importantly, the administration of  -Gal-
Cer not only enhanced the level of CS-specific CD8  T cell
response but also prolonged the duration of the response
(Fig. 2 A). We did not observe this strong enhancement of
the T cell responses by  -GalCer treatment when we ad-
ministered  -GalCer 2 d prior or 2 d after  -spz immuniza-
tion (data not shown). We found no difference in the num-
bers of CS-specific CD4  or CD8  T cells secreting IL-4
(data not shown), indicating that  -GalCer treatment pri-
marily enhances antigen-specific Th1-type responses in our
experimental system. Because we obtained similar results in
both BALB/c and B10.D2 mice, we conclude that the adju-
vant effect of  -GalCer is not influenced by the different
genetic backgrounds of these mice (data not shown).
To determine whether  -GalCer also enhances CS-spe-
cific T cell responses upon immunization with recombi-
nant viruses, we administered  -GalCer to BALB/c mice
at the same time as subcutaneous immunization with a
suboptimal dose of AdPyCS. 10 d later, we obtained sple-
nocytes from these mice and determined the number of
CS-specific T cells secreting IFN-  or IL-4 by an
ELISPOT assay. The number of both CS-specific CD4 
and CD8  T cells secreting IFN-  elicited in  -GalCer–
treated, AdPyCS-immunized mice was more than 10-fold
higher than that of T cells from a group of mice immu-
nized with the virus alone (Fig. 2 B). When we used
SIN(Mal), we found that  -GalCer treatment also signifi-
cantly increased the number of CS-specific CD8  T cells
secreting IFN-  (Fig. 2 C). We next determined if the ad-
juvant activity of  -GalCer is a phenomenon related spe-
cifically to the H-2Kd–restricted CD8  T cell epitope of
the CS, or can be applied to different epitopes. For this
purpose we immunized BALB/c mice with a recombinant
Table I.  -GalCer Enhances Protective Immunity Induced by 
Malaria Immunogens
Immunogen
No. of mice
protected
/no. challenged
Percent protection
(no parasitemia)
 -spza 6/30 20
 -spz    -GalCer 28/30 93
AdP CSa 2/30 7
AdP CS    -GalCer 24/30 80
 -GalCer 0/30 0
None 0/30 0
aBALB/c mice were immunized either intravenously with 104  -spz or
subcutaneously with 107 PFU of AdP CS.621 Gonzalez-Aseguinolaza et al.
Sindbis virus expressing a H-2Dd–restricted CD8  T cell
epitope from the p18 protein of HIV (28).  -GalCer coad-
ministration increased the number of p18-specific IFN- –
secreting CD8  T cells induced by immunization with
SIN(p18) fourfold (Fig. 2 C). Taken together these results
indicate that the enhancement of the cellular immune re-
sponse by treatment with  -GalCer is independent of the
antigen delivery system (attenuated pathogen or recombi-
nant virus) and the epitope.
The Adjuvant Activity of  -GalCer Requires CD1d Mole-
cules, V 14 NKT Cells, and IFN- . Next, we investigated
the cellular mechanism underlying  -GalCer’s adjuvant ac-
tivity, using mice lacking CD1d molecules, and those defi-
cient in T cells expressing the canonical NKT cell receptor.
Briefly, we immunized these knockout mice, along with
wild-type controls, with a suboptimal dose of  -spz with or
without   -GalCer treatment. 2 wk later, we challenged
these immunized mice, as well as nonimmunized controls,
with live sporozoites, and determined the levels of protec-
tive anti-malaria immunity. Administration of  -GalCer,
which increased the level of  -spz–induced protective im-
munity in wild-type mice, failed to enhance protective im-
munity in CD1d-deficient mice, as well as in J 281-defi-
cient mice, which lack V 14 NKT cells (Fig. 3 A). These
results indicate that the adjuvant activity of  -GalCer is de-
pendent on both CD1d molecules and V 14 NKT cells.
To further demonstrate the importance of CD1d mole-
cules and V 14 NKT cells for the adjuvant activity of  -Gal-
Cer, we measured the number of CS-specific CD8  T cells
in  -spz-immunized,  -GalCer–treated or untreated mice
deficient in either CD1d or V 14 NKT cells. As shown in
Fig. 3 B,  -GalCer treatment failed to increase the number
of CS-specific CD8  T cells induced by  -spz immuniza-
tion in CD1d-deficient mice compared with that of un-
treated mice, indicating that  -GalCer requires CD1d to
enhance the CS-specific CD8  T cell response. Interest-
ingly, in  -spz–immunized and  -GalCer–treated, J 281-
deficient mice, the number of CS-specific CD8  T cells
was slightly but significantly increased compared with that
of untreated mice (Fig. 3 B). However, this increase did
not reach the level of  -GalCer–treated,  -spz–immunized
wild-type mice (Fig. 3 B), and did not enhance the level of
protective anti-malaria immunity (Fig. 3 A). These find-
ings, therefore, demonstrate the importance of V 14 NKT
cells in mediating the adjuvant effect of  -GalCer.
Lastly, in order to gain insight into the molecular mech-
anism underlying  -GalCer’s adjuvant activity, we immu-
nized mice lacking the IFN-  receptor (IFN-  R / ) with
 -spz with or without  -GalCer cotreatment, and 10 d
later, we analyzed the numbers of CS-specific IFN- -secret-
ing CD8  and CD4  T cells using an ELISPOT assay.  -Gal-
Cer coadministration failed to augment the number of
CS-specific IFN- –secreting CD8  and CD4  T cells in
the   -spz–immunized knockout mice (Fig. 4 A). It has
been reported that mice deficient in different molecules
such as GM-CSF receptor  -chain (32) and Fas (33) are
also partially deficient in NKT cells. To exclude the possi-
bility that the absence of the IFN-  receptor results in a de-
creased number and/or defective function of NKT cells,
we analyzed the presence and the function of NKT cells in
these IFN-  R  /  mice by CD1d/ -GalCer tetramer
staining and ELISPOT assay. Flow cytometric analysis us-
ing CD1d/ -GalCer tetramers revealed that the percentage
of  -GalCer–specific NKT cells among hepatic lympho-
cytes in IFN-  R /  mice is similar to that in wild-type
mice (Fig. 4 B). In addition, the number of  -GalCer–spe-
cific cells secreting IFN-  in the liver (Fig. 4 C) and spleen
Figure 2.  -GalCer increases the level of antigen-specific T cell re-
sponses elicited by various vaccines. (A) A group of BALB/c mice was
immunized subcutaneously with  -spz together with or without adminis-
tration of  -GalCer by the same route, and 2 or 6 wk later splenic lym-
phocytes were isolated and the number of IFN- –secreting CS-specific
CD8  (black bars) and CD4  (white) T cells was determined by an
ELISPOT assay. (B) A group of BALB/c mice was immunized subcuta-
neously with AdPyCS together with or without subcutaneous administra-
tion of  -GalCer ( ) or vehicle ( ). 2 wk later the number of IFN-  se-
creting CS-specific CD8  (black bars) and CD4  (white bars) T cells was
determined by an ELISPOT assay. (C) A group of BALB/c mice was
immunized subcutaneously with SIN(Mal) or SIN(p18) together with or
without subcutaneous administration of  -GalCer. 2 wk later the number
of IFN-  secreting CS-specific and p18-specific CD8  T cells was deter-
mined by an ELISPOT assay. The data represent one of two experiments
with similar results and are expressed as the mean values   SD of three mice.622  -Galactosylceramide Enhances Malaria Vaccines
(data not shown) of wild-type and IFN-  R  /  mice is
similar, eliminating the possibility that the lack of adjuvant
activity was due to a defect in the NKT cell population.
Collectively, these results indicate that  -GalCer’s adjuvant
activity is dependent on IFN-  production.
Discussion
Our current study addresses the ability of the NKT cell
ligand  -GalCer to modulate acquired anti-malaria immu-
nity. We found that  -GalCer administered to mice im-
munized with a suboptimal dose of irradiated P. yoelii
sporozoites or with suboptimal doses of recombinant vi-
ruses expressing malarial antigens greatly enhances protec-
tive anti-malaria immunity.
The main immune components affected by  -GalCer
administration are malaria-specific CD8  and CD4  T cells
that secrete IFN- . The levels of the humoral response and
the Th2 response are unaltered by this treatment. Adminis-
tration of  -GalCer increased the number of IFN- –secret-
ing CS-specific CD8  and CD4  T cells induced by  -spz
immunization approximately sevenfold and fivefold, re-
spectively. Furthermore, the level of CS-specific T cell re-
sponses remains much higher at 6 wk after  -spz immuni-
zation in  -GalCer–treated mice compared with that in
nontreated mice. As protective immunity against the liver
stages of malaria is primarily mediated by CD8  T cells, as
well as CD4  T cells, and requires production of IFN-  (8,
9, 34), it is not surprising that the level of anti-malaria
protection was increased by  -GalCer treatment. This ad-
juvant effect of  -GalCer was also observed in  -GalCer–
treated mice immunized with recombinant viruses express-
ing either the P. yoelii CS protein or the H-2Kd–restricted
CD8  T cell epitope of this protein. These results confirm
and extend the data obtained by  -spz immunization, indi-
Figure 3. The adjuvant activ-
ity of  -GalCer requires CD1d
molecules and V 14 NKT
cells. (A) Groups of CD1d-defi-
cient (CD1 / ), V 14 NKT
(J 281 / ) deficient and wild-
type (WT) mice on a BALB/c
background were immunized in-
travenously with  -spz together
with intraperitoneal administra-
tion of  -GalCer ( ) or vehicle
( ). 2 wk later these and nonim-
munized mice were challenged
with viable sporozoites, and the
parasite burden in the liver was measured as described in Fig. 1. (B) Identical groups of mice as described in panel A were immunized with  -spz with in-
traperitoneal injection of  -GalCer ( ) or vehicle ( ). 2 wk later the number of IFN-  secreting CS-specific CD8  T cells in the spleens was deter-
mined by an ELISPOT assay. Asterisk (*) indicates a significant (P   0.01) difference between the two values using an unpaired t test. The results reflect
two experiments with similar results and are expressed as the mean values   SD of five (A) or three (B) mice.
Figure 4. The adjuvant activity of  -GalCer is abolished in IFN-  recep-
tor-deficient mice. (A) Groups of IFN-  receptor-deficient (IFN-  R / )
and wild-type (WT) mice on a B10.D2 background were immunized
intravenously with  -spz together with intraperitoneal administration of
 -GalCer ( ) or vehicle ( ). 2 wk later splenic lymphocytes were ob-
tained and the number of IFN-  secreting CS-specific CD8  (black bars)
and CD4  (white bars) T cells were determined by an ELISPOT assay.
(B) Hepatic lymphocytes were obtained from IFN-  R /  and wild-type
mice and stained with PE-labeled CD1d/ -GalCer tetramer and FITC-
labeled anti-CD3 antibody, and the percentage of  -GalCer–specific T
cells was determined by flow cytometric analysis. The number indicated
in the upper right corners represents the percentage of double-positive
cells among the liver lymphoid cell population. (C) Hepatic lymphocytes
were obtained from IFN-  R /  (black bars) or WT (white bars) mice,
and the number of IFN-  or IL-4 secreting  -GalCer–specific cells were
determined by an ELISPOT assay. Results are expressed as the mean val-
ues   SD of five mice.623 Gonzalez-Aseguinolaza et al.
cating that malaria-specific CD8  and CD4  T cell re-
sponses are enhanced by  -GalCer administration regardless
of the type of immunogen used, parasite or recombinant vi-
rus. We also demonstrated that the CD8  T cell response
enhanced by  -GalCer administration is independent of the
CD8  T cell epitope used, as the immune response induced
by a recombinant Sindbis virus expressing a H-2Dd–restricted
T cell epitope of HIV was also enhanced.
 -GalCer’s ability to augment the level of protective
anti-malaria immunity induced by  -spz immunization re-
quires both CD1d molecules and V 14 NKT cells. With-
out these components,  -GalCer was unable to increase
the protection elicited by a suboptimal dose of the immu-
nogen. Although both CD1d molecules and V 14 NKT
cells were needed for  -GalCer’s ability to augment pro-
tective anti-malaria immunity, we detected a noticeable in-
crease in the number of CS-specific CD8  T cells in
J 281-deficient mice after  -GalCer treatment. It is possi-
ble that the high degree of genetic heterogeneity in these
mice affects the T cell response and causes this moderate
increase. Alternatively, CD1d-reactive, non-V 14 NKT
cells may exist in J 281–deficient mice. Further investiga-
tion is required to explain this result.
While the precise molecular mechanism of the adjuvant
effect of  -GalCer remains to be fully clarified, our finding
that these activities of  -GalCer are eliminated in mice
lacking IFN-  receptor indicates that IFN-  is important
in mediating the adjuvant effect of  -GalCer. Studies by a
number of different investigators clearly show that IFN-  is
secreted by both NKT and NK cells after  -GalCer treat-
ment (22, 24, 25). It is possible that IFN-  secreted by
NKT and/or NK cells acts on antigen-presenting cells, by
up-regulating the MHC class I processing machinery, e.g.,
TAP, proteasome subunits, and class I heavy chains. Alter-
natively, IFN-  may enhance the acquired cell-mediated
immune response by directly acting on antigen-specific
CD8  T cells. Nevertheless, the exact role of IFN-  and
other critical molecules requires further investigation.
Our kinetic studies show that  -GalCer displays a maxi-
mal adjuvant effect only when the glycolipid is coadminis-
tered with  -spz. Administration of  -GalCer 2 d before or
after immunization with  -spz fails to elicit adjuvant activ-
ity. A recent study on the in vivo kinetics of NKT cells af-
ter  -GalCer administration using CD1d/ -GalCer tetra-
mers indicates that murine NKT cells, especially those in
the liver where they constitute 20–30% of the lymphocyte
population, are promptly activated, secrete large amounts
of IFN-  and IL-4, and readily disappear 5 h after stimula-
tion. Interestingly, this acute disappearance of  -GalCer–
activated NKT cells was also confirmed by phenotypic
analysis of the peripheral blood of cancer patients treated
with  -GalCer (unpublished data).
As previously shown by various investigators, NKT cell
activation not only causes activation of NK cells but also
proliferation of memory CD4  and CD8  T cells (26), or
induction of the early activation marker CD69 on the sur-
face of T cells and B cells (22), suggesting a role for acti-
vated NKT cells in initiating T cell and B cell responses. It
is pertinent to note that a recent study has shown that ad-
ministration of  -GalCer to mice immunized with a T cell
lymphoma enhances the generation of tumor-specific cyto-
toxic T cells (22). In this regard, our study indicates for the
first time that  -GalCer–activated NKT cells play a role in
the induction of “protective immunity” where specific
CD8  T cells are the primary effectors.
In conclusion, by showing that  -GalCer–activated
NKT cells enhance protective anti-malaria immune re-
sponses, our studies present evidence for a role of NKT cells
in bridging innate and adaptive immunity. Our current
findings on the adjuvant activity of  -GalCer might be ap-
plicable to various other intracellular microbial pathogens in
addition to malaria, as well as to tumor models. Finally, as it
has been demonstrated that  -GalCer can also stimulate hu-
man NKT cells (35, 36), these findings are expected to con-
tribute to the understanding of the role of human NKT
cells, and the design of novel, more effective vaccines.
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